From the Univ. Lille, CHU Lille, Odontologie, F-59000 Lille, France.
Exp Clin Transplant. 2024 Jun;22(6):411-420. doi: 10.6002/ect.2024.0095.
In this systematic review, we aimed to shed light on the frequency of dysgeusia among patients who had received hematopoietic stem cell transplantation and to determine factors that may be conducive to this buccal symptom.
We conducted a systematic review of the literature on frequency of dysgeusia in patients who received hematopoietic stem cell transplant. We searched PubMed, PMC-PubMed, and Web of Science and followed the Preferred Reporting Items for Systematic reviews and Meta-analyses statement.
We identified 15 studies. The global frequency of dysgeusia varied greatly, ranging from 16.7% to 95%. Allogeneic stem cell transplant, including cells from other individuals, had more secondary effects than autologous transplant. Rate of dysgeusia was higher at the beginning of treatment. We found some differences according to populations, with dysgeusia increasing with age. Pediatric patients recovered more quickly, perhaps as a result of their faster cell division and development of taste receptors.
Dysgeusia can greatly affect quality of life during graft treatment. The frequency can vary according to a number of factors, which are different targets in treatment. Symptom management during transplant seems to contribute to overall improvement in treatment.
本系统评价旨在阐明接受造血干细胞移植患者味觉障碍的发生率,并确定可能有利于该口腔症状的因素。
我们对接受造血干细胞移植患者味觉障碍发生率的文献进行了系统评价。我们检索了 PubMed、PMC-PubMed 和 Web of Science,并遵循系统评价和荟萃分析的首选报告项目声明。
我们确定了 15 项研究。味觉障碍的全球发生率差异很大,范围从 16.7%到 95%。包括来自其他人的细胞的异基因干细胞移植比自体移植有更多的副作用。治疗开始时味觉障碍的发生率更高。我们根据人群发现了一些差异,味觉障碍随着年龄的增长而增加。儿科患者恢复得更快,这可能是由于他们更快的细胞分裂和味觉感受器的发育。
味觉障碍会极大地影响移植物治疗期间的生活质量。频率可能因多种因素而异,这些因素是治疗的不同靶点。移植期间的症状管理似乎有助于整体改善治疗。